African Drug Discovery: The Potential of AI and Emerging Technologies to Support a Future of 2.5 Billion African consumers

By Nii Simmonds

In the developing world, where health challenges abound, Artificial Intelligence (AI) and other cutting-edge technologies are transforming the pharmaceutical and life science industries. With more than 2.5 billion people projected to inhabit Africa alone by 2050, access to healthcare continues to be a major issue for many people. The potential of drug discovery through such innovative solutions as AI-powered drug discovery for tropical diseases could be extremely beneficial in helping bridge this gap and providing a better quality of life for African citizens. In this article, we'll examine how these emerging technologies can help create a brighter future for Africans, the importance of drug discovery collaborations, as well as the challenges that must still be overcome.

The Current State of African Drug Discovery

The current state of African drug discovery is quite dire. The lack of infrastructure and investment in the continent has resulted in a dearth of data and knowledge about African disease states. This, coupled with the lack of capacity building within the region, has resulted in a real lag in innovation when it comes to new drug development for Africa. However, a burgeoning cohort of African entrepreneurs and innovators is spearheading a revolution in therapy and pharmaceuticals on the continent. This is motivated by a lack of African drug production which has left many Africans with limited access to essential medicines. Several African scientists and biologists are joining forces to raise funding and attract venture capital for biotech and drug discovery initiatives, in an attempt to redress these difficulties and enhance the health of Africans.

Setting up pharmaceutical production in Africa comes with its challenges, but if these can be overcome, the potential benefits are enormous. Job creation and an improved economy through the development of tier one, two and three suppliers for drug production capabilities will see Africans take greater control over their own health care. Moreover, access to essential medications will be increased. African entrepreneurs and innovators have the power to create a transformational pharmaceutical and biotech sector - if they take on this challenge, the rewards may indeed be far reaching.

Capital and Regulatory Challenges

African pharmaceutical companies face many challenges when it comes to raising capital. Many African countries do not have the same level of investment as developed countries, so African biotech and pharmaceutical companies often must rely on foreign partners for funding. This can create several challenges, including a lack of control over their own products, operations, strategy, and intellectual property.

Another challenge is regulatory hurdles. In many African countries, the regulatory landscape is still evolving and there are often not well-established procedures for approving new drugs and medical devices. This can make it difficult for African pharmaceutical companies to get their products onto the market in a timely manner. Another challenge is the lack of cooperation between African countries and regional bodies on regulations. If African governments can work together to streamline regulations and create a more conducive business environment, it will be easier for African pharmaceutical and biotech companies to thrive.

?

The potential of AI and emerging technologies in African drug discovery

The use of AI and other emerging technologies in drug discovery is an exciting prospect with the potential to greatly impact the future of healthcare for tropical diseases in Africa. While AI has been used in drug discovery in developed countries, its potential is only now being fully realized due to access to cloud services. Recent advances in AI technology have led to significant improvements in its ability to identify and predict new therapeutic targets and to optimize existing drugs. These capabilities are particularly valuable in Africa, where there is a great need for new and improved treatments for many tropical diseases.

AI can expedite the drug discovery process, accelerating target identification and maximizing the efficacy of existing drugs. Its capabilities in predicting successful drug compounds will significantly increase the odds of success for development projects. Early use of AI for drug discovery has already caused a stir, and those African states and private entities which take advantage of this technology may become frontrunners in finding cutting-edge treatments for Africa's most urgent health issues, particularly tropical diseases neglected by Western pharmaceuticals.

Challenges and Opportunities

In recent years, the African continent has experienced rapid economic growth and development. This has created new challenges and opportunities for the healthcare sector, including in drug discovery. One of the biggest challenges facing Africa is the high burden of disease. According to the World Health Organization (WHO), Africa bears 24 percent of the global burden of disease, yet has only three percent of the world's health workforce and less than one percent of global health expenditure. This means that there is a huge disparity in access to healthcare between Africa and the rest of the world.

In addition to this, many African countries face significant challenges in terms of infrastructure and funding. This can make it difficult for researchers to access essential equipment and resources and can limit the scope of their work. However, despite these challenges, there are also many opportunities for drug discovery in Africa. The continent is home to a diverse range of cultures and languages, which can offer unique insights into disease etiology and treatment. In addition, the continent's vast biodiversity could provide novel leads for drug development. Africa is also an increasingly attractive destination for clinical trials due to its large population size and relatively low costs. This provides a great opportunity for pharmaceutical companies to test new drugs and therapies in a real-world setting. With its vast potential, Africa is an exciting place for drug discovery research. By harnessing emerging technologies such as AI, researchers can overcome some of the challenges.

Despite these challenges, there are also opportunities for African pharmaceutical companies to succeed. One opportunity is the growing middle class in many African countries. As incomes rise, more people will be able to afford quality healthcare products and services. This presents a huge potential market for African biotech and pharmaceutical companies.

?

The Future of African Drug Discovery

The African Union has identified health as one of its key priority areas, with a particular focus on increasing access to essential medicines. In order to achieve this, the African Union is committed to leveraging the talents of African scientists in the diaspora for drug discovery. The diaspora presents a unique opportunity to harness the skills and knowledge of Africans living outside the continent. These scientists have a deep understanding of the challenges faced by their home countries and are well positioned to contribute to solving these challenges. The tropical diseases burden is one of the biggest health challenges facing Africa. These diseases disproportionately affect poor and marginalized communities, and account for a large proportion of the continent's disease burden.

African researchers abroad have the capacity to bring their expertise in both traditional medicines and modern scientific methods to bear on this critical issue. According to WHO estimates, two billion people lack access to essential drugs, a difficulty that must be solved if we are to reach universal health coverage. African scientists can assist by engineering new treatments and ensuring they are available for those who need them most. Furthermore, with recent advancements in emerging technologies and AI, it is possible to expedite the process of creating new medications for tropical ailments.

In Conclusion

The African continent will grow from 1.4 billion to 2.5 billion people by 2050, and governments, innovators, and the diaspora must work together to develop indigenous African pharmaceuticals. The future leaders of the continent will expect no less from us. While infrastructure, base-load electricity, and talent are challenges, strategic planning can mitigate future challenges.

??

Author Bio:

Nii Simmonds

Nii Simmonds is Nonresident Senior Fellow with the Atlantic Council. Nii has expertise as an emerging market professional with a senior leadership background in emerging technologies and AI policy, supply chains, competitiveness, entrepreneurial ecosystems, diaspora engagement and corporate finance. Nii has previous management and P&L responsibility with Fortune 500 companies (Big Pharma & Biotech, Consumer Products, and Strategy Consulting). These roles have focused on strategic and long-term planning for various business units, and advising C-Level executives on growth strategy, joint-venture, and competitive strategy.